SUNITINIB TREATMENT OF RENAL ADJUVANT CANCER (S-TRAC): A RANDOMIZED, DOUBLE-BLIND, PHASE III STUDY OF SUNITINIB VS. PLACEBO IN SUBJECTS AT HIGH RISK OF RECURRENT RENAL CELL CARCINOMA (RCC)
暂无分享,去创建一个
J. Patard | A. Ravaud | R. Motzer | A. Pantuck | H. Pandha | D. George | M. Staehler | Anup Patel | L. Chen | P. Gerletti